Standout Papers

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-la... 2020 2026 2022 2024301
  1. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial (2020)
    Vivek Subbiah, Ulrik Lassen et al. The Lancet Oncology

Immediate Impact

62 standout
Sub-graph 1 of 22

Citing Papers

Digestive cancers: mechanisms, therapeutics and management
2025 Standout
From geroscience to precision geromedicine: Understanding and managing aging
2025 Standout
1 intermediate paper

Works of Kert Viele being referenced

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
2020 Standout
Comparison of methods for control allocation in multiple arm studies using response adaptive randomization
2019

Author Peers

Author Last Decade Papers Cites
Kert Viele 453 80 70 281 241 52 1.4k
Helena Geys 864 169 88 124 236 89 1.9k
Erica Brittain 602 220 19 133 149 56 2.2k
Joachim Röhmel 573 336 38 216 303 57 1.5k
Didier Renard 611 98 38 105 174 38 1.7k
J. Sunil Rao 434 103 294 221 106 71 1.8k
Joseph F. Heyse 427 167 30 494 61 63 2.2k
Alan J. Gross 375 57 104 147 100 66 1.5k
Jonathan French 203 38 43 82 209 61 1.9k
Luc Bijnens 190 55 120 417 287 74 2.1k
Takashi Sozu 201 101 4 277 152 78 1.3k

All Works

Loading papers...

Rankless by CCL
2026